Benz Advisory
Share:
Subscribe:

news.cision.com/
Benz Advisory/
Muvon Therapeutics Announces Successful Phase I Clinical Study in Female Patients with Stress Urinary Incontinence using a Novel Regenerative Cell Therapy/
Deana Mohr, CEO Muvon Therapeutics

2 of 2

Deana Mohr, CEO Muvon Therapeutics

Thu, Sep 08, 2022 09:05 CET

Deana Mohr, CEO Muvon Therapeutics

Medium resolution

Original resolution

Subscribe

©Cision

Privacy statement | Cookies | About | Content Policy | Contact

©Cision Privacy statement Cookies About Content Policy Contact